Lux Health Tech Acquisition Corp. Class A Common Stock
LUXA
LUXA was delisted on the 28th of October, 2022.
0 hedge funds and large institutions have $0 invested in Lux Health Tech Acquisition Corp. Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 72 closing their positions.
100% less funds holding
Funds holding: 72 → 0 (-72)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $301M → $0 (-$301M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 72
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$30.1M |
| 2 |
SC
Sculptor Capital
New York
|
-$20.2M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$18.1M |
| 4 |
WH
Wolfswood Holdings
New York
|
-$14.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$13.8M |
LUXA Hedge Fund Activity: Q4 2022 in Review
0 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA) for Q4 2022, worth a combined $0 — down 100% from $301M a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of LUXA and 0 opened new positions — a net loss of 72 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Empyrean Capital Partners, exiting entirely with an estimated $30.1M sold.
- 0 institutional investors held Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA) as of Q4 2022, down from 72 in Q3 2022.
- Funds reported $0 of Lux Health Tech Acquisition Corp. Class A Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Lux Health Tech Acquisition Corp. Class A Common Stock positions in Q4 2022 and 72 closed out, a net change of -72 holders.
- The largest Lux Health Tech Acquisition Corp. Class A Common Stock seller in Q4 2022 was Empyrean Capital Partners, an estimated $30.1M sold.
Based on aggregated 13F filings for Q4 2022.